VIA
SIOX

Vident Investment Advisory’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Vident Investment Advisory’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,944
Closed -$2.17M – 898
2015
Q3 		$2.17M Buy
+20,944
New +$2.46M 0.3% 59

Other funds holding SIOX

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vident Investment Advisory's SIOX Position: Q4 2015 in Review

Vident Investment Advisory sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2015, closing a stake of 20,944 shares — an estimated $2.17M sold.

Vident Investment Advisory first reported a position in SIOX in Q3 2015 and held it in 1 quarter. The position peaked at $2.17M in Q3 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q4 2015.

  • Vident Investment Advisory reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 20,944 Sio Gene Therapies Inc. Common Stock shares in Q4 2015, an estimated $2.17M.
  • Vident Investment Advisory first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • Vident Investment Advisory's Sio Gene Therapies Inc. Common Stock position peaked at $2.17M in Q3 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2015.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.